GLPwatch
Papers (12034)
Page 123 of 201, ranked by citation count.
- Semaglutide for Weight Reduction in Type 1 Diabetes: Promising Results With Uncertain Glycemic Impact.
- Classification of Non-Insulin Glucose Lowering Drugs.
- Liraglutide for Adolescents with Obesity.
- Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption.
- Direct Effect of the Synthetic Analogue of Glucagon-Like Peptide Type 1, Liraglutide, on Mature Adipocytes Is Realized through Adenylate-Cyclase-Dependent Enhancing of Insulin Sensitivity.
- Controlling Obesity and Metabolic Diseases by Hydrodynamic Delivery of a Fusion Gene of Exendin-4 and α1 Antitrypsin.
- Glucagon-Like Peptide-1-, but not Growth and Differentiation Factor 15-, Receptor Activation Increases the Number of Interleukin-6-Expressing Cells in the External Lateral Parabrachial Nucleus.
- Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists.
- GLP-1 receptor agonist liraglutide facilitates rotator cuff healing by reducing tendon cell inflammation and endoplasmic reticulum stress through the GLP-1R-AMPK/SIRT1 pathway.
- Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli-SWITCH study.
- Anti-obesity medications in the management of heart failure with preserved ejection fraction: available evidence and next STEPS.
- Obesity update: cardiovascular risk and therapeutic innovations (focus on semaglutide and tirzepatide).
- Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus.
- Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial.
- The mechanism of liraglutide on promoting osteogenesis via macrophages polarization under the inflammatory and oxidative stress in osteoporosis.
- Exploring beyond numeric weight loss: The metabolic effects of semaglutide.
- Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide.
- Effect of semaglutide 2.4 mg on use of antihypertensive and lipid-lowering treatment in five randomized controlled STEP trials.
- Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study.
- Disruptions in Aesthetic Medicine: A Global Analysis of GLP-1 Agonists Using Punctuated Equilibrium Framework.
- Insights into the Mechanism of Action of Tirzepatide: A Narrative Review.
- Liraglutide for the Treatment of Obesity: Analyzing Published Reviews.
- Unmasking Semaglutide-Induced Gastroparesis: The Dangers of Rapid Dose Escalation in a Diabetic Patient.
- Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study.
- Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: Insights from meta-analysis of randomised controlled trials and real-world evidence.
- Semaglutide attenuates diabetic retinopathy progression via ameliorating retinal vasculopathy and oxidative stress in vivo and in vitro.
- Tirzepatide (Mounjaro) for type 2 diabetes.
- Semaglutide-Induced Small Bowel Pseudo-Obstruction and Ileitis in a Patient With Type 2 Diabetes: A Case Report.
- Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
- Liraglutide alters DPP4 in the circumvallate papillae of type 2 diabetic rats.
- Influence and significance of intervening diabetes microRNA expression profile of NOD mice with exendin-4.
- Examination of a Viral Infection Mimetic Model in Human iPS Cell-Derived Insulin-Producing Cells and the Anti-Apoptotic Effect of GLP-1 Analogue.
- Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study.
- Liraglutide pharmacotherapy reduces body weight and improves glycaemic control in juvenile obese/hyperglycaemic male and female rats.
- A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide.
- Influence of Buffering Capacity, pH, and Temperature on the Stability of Semaglutide: A Preformulation Study.
- <i>KCNQ1</i> variant rs163184 is a potential biomarker of glycemic response to exenatide.
- GLP-1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk.
- Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients.
- Evaluating the Efficacy and Safety of Tirzepatide on Glycaemic and Non-glycaemic Outcomes in Diabetes: A Systematic Review of Meta-Analyses.
- Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes.
- Exenatide alters absorption of hydrocortisone in a diabetic patient with panhypopituitarism: iatrogenic adrenal insufficiency.
- The role of partial area under the curve and maximum concentrations in assessing the bioequivalence of long-acting injectable formulation of exenatide_A sensitivity analysis.
- Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration.
- Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial.
- Novel neural pathways targeted by GLP-1R agonists and bariatric surgery.
- Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland.
- Anorgasmia following initiation of GLP-1 agonist.
- Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus.
- A review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes.
- Weight Loss of Over 100 lbs in a Patient of Prader-Willi Syndrome Treated With Glucagon-Like Peptide-1 (GLP-1) Agonists.
- Relative efficacy of GLP-1 and GLP-1/GIP receptor agonists in the prevention of alcohol-use disorders using a target trial emulation approach.
- Design of a novel long-acting dual GLP-1/GIP receptor agonist.
- Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide.
- The effect of liraglutide on renal function in type 2 diabetes: a meta-analysis of randomized controlled studies.
- HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial.
- The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data.
- Dulaglutide-induced cerebral venous thrombosis in a patient with type 2 diabetes mellitus.
- NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?
- Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: A pharmacovigilance study and literature review.